Quo Vadis, Conventional Radiopharmaceutical for Radionuclide Therapy?

S. Ezziddin (Homburg)

A shift from conventional I131-based nuclear medicine therapy towards more recent approaches addressing other targets with various, theranostic-compatible radiopharmaceuticals is noticeable in Nuclear Medicine.

The presentation will cover conventional radionuclide therapies with licensed products as well as newer approaches. Modalities such as peptide receptor radionuclide therapy (PRRT), bone-targeted radionuclide therapy (BTRT), radioimmunotherapy (RIT), radioembolization (SIRT) and PSMA-targeted treatment will be included.

In the coming decade, we will be witnessing a rise, probably a magnificent rise, in the perceived importance of targeted tumor therapy via radiopharmaceuticals. Improvements in targeting, selection of molecules and measures for reducing toxicity will contribute to this development, such as seen in PRRT and PSMA-targeted therapy. Many issues will have to be resolved in terms of creating evidence of higher levels and finding or guiding adequate regulatory solutions to ensure supply of patient care.

References: